Search

Author/Creator Dholaria, B.

1. P354: REAL-WORLD ANALYSIS OF THE RISKS OF THROMBOTIC AND BLEEDING EVENTS IN PATIENTS RECEIVING PEGYLATED ASPARAGINASE FOR TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA. (23rd June 2022)

Authors:
Mautner, B.; Brewer, B.; Mort, J.; Pierce, E.; Ghamsari, F.; Dibenedetto, S.; Morse, E.; Wells, L.; Morris, A.; Allen, C.; Patel, I.; D'Souza, D.; Jackson, C.; Perciavalle, M.; Yelvington, B.; Miller, R.; Abernathy, K.; Walsh, K.; Wolfe, H.; Locke, S.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
254
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. P526: REAL-WORLD COMPARISON OF DIFFERENT TREATMENT MODALITIES FOR FAVORABLE RISK ACUTE MYELOID LEUKEMIA: STANDARD DOSE ANTHRACYCLINE VS HIGH DOSE ANTHRACYCLINE VS ADDITION OF GEMTUZUMAB OZOGAMICIN. (23rd June 2022)

Authors:
Mort, J.; Brewer, B.; Mautner, B.; Dibenedetto, S.; Pierce, E.; Morse, E.; Wells, L.; Ghamsari, F.; Morris, A.; Clark, S.; Reid, J.; Patel, I.; Jackson, C.; Perciavalle, M.; Yelvington, B.; Miller, R.; Abernathy, K.; Wolfe, H.; Locke, S.; Zeidner, J.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
425
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. P897: UPDATED RESULTS FROM THE ONGOING PHASE 1 STUDY OF ELRANATAMAB, A BCMA TARGETED T-CELL REDIRECTING IMMUNOTHERAPY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA. (23rd June 2022)

Authors:
Dalovisio, A.; Bahlis, N.; Raje, N.; Costello, C.; Dholaria, B.; Solh, M.; Levy, M.; Tomasson, M.; Dube, H.; Damore, M.; Jiang, S.; Basu, C.; Skoura, A.; Chan, E.; Trudel, S.; Jakubowiak, A.; Chu, M.; Gasparetto, C.; Sebag, M.; Lesokhin, A.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
788
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. S183: NOVEL COMBINATION IMMUNOTHERAPY FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1B RESULTS FOR TALQUETAMAB (A GPRC5D X CD3 BISPECIFIC ANTIBODY) IN COMBINATION WITH DARATUMUMAB. (23rd June 2022)

Authors:
van de Donk, N. W.; Bahlis, N.; Mateos, M.-V.; Weisel, K.; Dholaria, B.; Garfall, A. L.; Goldschmidt, H.; Martin, T. G.; Morillo, D.; Reece, D. E.; Hurd, D.; Rodríguez-Otero, P.; Bhutani, M.; D'Souza, A.; Oriol, A.; Askari, E.; San-Miguel, J. F.; Kortüm, K. M.; Vishwamitra, D.; Xin Wang Lin, S.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
84
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. S188: TECLISTAMAB IN COMBINATION WITH DARATUMUMAB, A NOVEL, IMMUNOTHERAPY-BASED APPROACH FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1B RESULTS. (23rd June 2022)

Authors:
Rodriguez Otero, P.; D'Souza, A.; Reece, D.; van de Donk, N. W.; Chari, A.; Krishnan, A.; Martin, T.; Mateos, M. V.; Morillo, D.; Hurd, D.; Rosinol, L.; Balari, A. S.; Wäsch, R.; Vishwamitra, D.; Wang Lin, S. X.; Prior, T.; Vandenberk, L.; Smit, M.-A. D.; Oriol, A.; Dholaria, B.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
89
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search